Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment
- PMID: 26015406
- PMCID: PMC4558145
- DOI: 10.18632/oncotarget.3827
Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment
Abstract
Accumulating evidence has suggested that myristoylated alanine-rich C-kinase substrate (MARCKS) is critical for regulating multiple pathophysiological processes. However, the molecular mechanism underlying increased phosphorylation of MARCKS at Ser159/163 (phospho-MARCKS) and its functional consequence in neoplastic disease remain to be established. Herein, we investigated how phospho-MARCKS is regulated in breast carcinoma, and its role in the context of chemotherapy. In a screen of patients with breast tumors, we find that the abundance of phospho-MARCKS, not MARCKS protein per se, increased in breast cancers and positively correlated with tumor grade and metastatic status. Among chemotherapeutic agents, mitotic inhibitors, including paclitaxel, vincristine or eribulin, notably promoted phospho-MARCKS accumulation in multiple breast cancer cells. We further show that phospho-MARCKS acted upstream of Src activation upon paclitaxel exposure. Reduction of phospho-MARCKS by knockdown of MARCKS or pharmacological agents increased paclitaxel sensitivity. Particularly, a known phospho-MARCKS inhibitor, MANS peptide, was demonstrated to increase paclitaxel efficacy and attenuate angiogenesis/metastasis of xenografted breast cancer cells by decreasing abundance of phospho-MARCKS and messages of inflammatory mediators. Our data suggest that unresponsiveness of breast cancer to paclitaxel treatment is, at least in part, mediated by phospho-MARCKS and also provide an alternative therapeutic strategy against breast cancer by improving taxanes sensitivity.
Keywords: MANS peptide; breast cancer; mitotic inhibitor; paclitaxel; phospho-MARCKS.
Conflict of interest statement
The authors declare that they have no competing financial interests with the study.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4558145/bin/oncotarget-06-15194-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4558145/bin/oncotarget-06-15194-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4558145/bin/oncotarget-06-15194-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4558145/bin/oncotarget-06-15194-g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4558145/bin/oncotarget-06-15194-g005.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4558145/bin/oncotarget-06-15194-g006.gif)
Similar articles
-
A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis.Oncogene. 2014 Jul 10;33(28):3696-706. doi: 10.1038/onc.2013.336. Epub 2013 Aug 19. Oncogene. 2014. PMID: 23955080 Free PMC article.
-
Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.Am J Respir Crit Care Med. 2014 Nov 15;190(10):1127-38. doi: 10.1164/rccm.201408-1505OC. Am J Respir Crit Care Med. 2014. PMID: 25318062 Free PMC article.
-
Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19. FEBS J. 2013. PMID: 23876235
-
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.Surg Clin North Am. 2003 Aug;83(4):943-71. doi: 10.1016/S0039-6109(03)00071-9. Surg Clin North Am. 2003. PMID: 12875604 Review.
-
Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy.Cancer Chemother Pharmacol. 2017 Nov;80(5):909-917. doi: 10.1007/s00280-017-3398-2. Epub 2017 Jul 24. Cancer Chemother Pharmacol. 2017. PMID: 28741098 Review.
Cited by
-
Integrated analysis identifies microRNA-188-5p as a suppressor of AKT/mTOR pathway in renal cancer.Cancer Sci. 2023 Aug;114(8):3128-3143. doi: 10.1111/cas.15832. Epub 2023 May 18. Cancer Sci. 2023. PMID: 37199297 Free PMC article.
-
The Role of MARCKS in Metastasis and Treatment Resistance of Solid Tumors.Cancers (Basel). 2022 Oct 8;14(19):4925. doi: 10.3390/cancers14194925. Cancers (Basel). 2022. PMID: 36230850 Free PMC article. Review.
-
MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer.Cells. 2022 Sep 19;11(18):2926. doi: 10.3390/cells11182926. Cells. 2022. PMID: 36139501 Free PMC article.
-
The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines.Int J Mol Sci. 2022 May 23;23(10):5846. doi: 10.3390/ijms23105846. Int J Mol Sci. 2022. PMID: 35628654 Free PMC article.
-
Transcriptome Analysis of Liver Cancer Cell Huh-7 Treated With Metformin.Front Pharmacol. 2022 Mar 23;13:822023. doi: 10.3389/fphar.2022.822023. eCollection 2022. Front Pharmacol. 2022. PMID: 35401213 Free PMC article.
References
-
- Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi25–30. - PubMed
-
- McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96–132. - PubMed
-
- Cobleigh MA. Other options in the treatment of advanced breast cancer. Semin Oncol. 2011;38(Suppl 2):S11–16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous